journal article·2025-03-03Open access

Emulsion-Based Encapsulation of Fibrinogen with Calcium Carbonate for Hemorrhage Control

Henry T. Peng, Tristan Bonnici, Yanyu Chen, Christian Kastrup, Andrew Beckett

Abstract

Hemorrhage, particularly non-compressible torso bleeding, remains the leading cause of preventable death in trauma. Self-propelling hemostats composed of thrombin-calcium carbonate (CaCO3) particles and protonated tranexamic acid (TXA+) have been shown to reduce blood loss and mortality in severe bleeding animal models. To further enhance both hemostatic and self-propelling properties, this study was to investigate fibrinogen-CaCO3 particles prepared via a water-oil-water (W/O/W) emulsion method. The particles were characterized using light and fluorescence microscopy, gel electrophoresis, rotational thromboelastometry (ROTEM), and video motion tracking. The method produced spherical micrometer-sized particles with various yields and fibrinogen content, depending on the preparation conditions. The highest yield was achieved with sodium carbonate (SC), followed by ammonium carbonate (AC) and sodium bicarbonate (SBC). AC and paraffin generated smaller particles compared to SC and heptane, which were used as the carbonate source and oil phase, respectively. Fibrinogen incorporation led to an increase in particle size, indicating a correlation between fibrinogen content and particle size. Fluorescence microscopy confirmed successful fibrinogen encapsulation, with various amounts and hemostatic effects as assessed by gel electrophoresis and ROTEM. Combining fibrinogen-CaCO3 particles with TXA+ and thrombin-CaCO3 particles showed synergistic hemostatic effects. All fibrinogen-encapsulated particles exhibited self-propulsion when mixed with TXA+ and exposed to water, regardless of fibrinogen content. This study advances current hemostatic particle technology by demonstrating enhanced self-propulsion and fibrinogen incorporation via the W/O/W emulsion method. Further optimization of the encapsulation method could enhance the effectiveness of fibrinogen-CaCO3 particles for hemorrhage control.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Trauma, Hemostasis, Coagulopathy, Resuscitation · Hemostasis and retained surgical items · Blood transfusion and management

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Defence Research and Development Canada, Toronto Research Centre, Toronto, ON M3K 2C9, Canada

Department of Nanotechnology Engineering, University of Waterloo, Waterloo, ON N2L 3G1, Canada

Michael Smith Laboratories and Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC V6T 1Z4, Canada

Versiti Blood Research Institute, Milwaukee, WI 53226, USA

St. Michael’s Hospital, University of Toronto, Toronto, ON M5B 1W8, Canada

Royal Canadian Medical Services, Ottawa, ON K1A 0K2, Canada

Funding

Defence Research and Development Canada

References (75)

Show source-provided references
1. Biomaterials and advanced technologies for hemostatic management of bleeding10.1002/adma.201700859 ↗
2. Death on the battlefield (2001–2011): Implications for the future of combat casualty care10.1097/TA.0b013e3182755dcc ↗
3. Mortality review of us special operations command battle-injured fatalities10.1097/TA.0000000000002610 ↗
4. Haemorrhage control in severely injured patients10.1016/S0140-6736(12)61224-0 ↗
5. Impact of hemorrhage on trauma outcome: An overview of epidemiology, clinical presentations, and therapeutic considerations
6. Establishing a regional trauma preventable/potentially preventable death rate10.1097/SLA.0000000000002999 ↗
7. Injuries to the abdomen from explosion10.1007/s40719-017-0079-x ↗
8. The use of viscoelastic haemostatic assays in the management of major bleeding: A British society for haematology guideline10.1111/bjh.15524 ↗
9. Prehospital control of life-threatening truncal and junctional haemorrhage is the ultimate challenge in optimizing trauma care; a review of treatment options and their applicability in the civilian trauma setting10.1186/s13049-016-0301-9 ↗
10. Systematic review of prehospital haemostatic dressings10.1136/jramc-2018-001066 ↗
11. Emerging approaches to pre-hospital hemorrhage control: A narrative review10.21037/atm-20-5452 ↗
12. Biomaterials for hemorrhage control
13. Novel wound sealants: Biomaterials and applications10.1586/erd.10.40 ↗
14. Topical hemostatic agents and dressings in the prehospital setting10.1097/ACO.0000000000000166 ↗
15. Biomaterials for hemostasis10.1146/annurev-bioeng-012521-101942 ↗
16. Advances in topical hemostatic agent therapies: A comprehensive update10.1007/s12325-020-01467-y ↗
17. Mecwan, M., Li, J., Falcone, N., Ermis, M., Torres, E., Morales, R., Hassani, A., Haghniaz, R., Mandal, K., and Sharma, S. (2022). Recent advances in biopolymer-based hemostatic materials. Regen. Biomater., 9.10.1093/rb/rbac063 ↗
18. Shao, H., Wu, X., Xiao, Y., Yang, Y., Ma, J., Zhou, Y., Chen, W., Qin, S., Yang, J., and Wang, R. (2024). Recent research advances on polysaccharide-, peptide-, and protein-based hemostatic materials: A review. Int. J. Biol. Macromol., 261.10.1016/j.ijbiomac.2024.129752 ↗
19. Targeting polysaccharides such as chitosan, cellulose, alginate and starch for designing hemostatic dressings10.1016/j.carbpol.2022.119574 ↗
20. Research status and development potential of composite hemostatic materials10.1039/D0TB00906G ↗
21. Ruggedized self-propelling hemostatic gauze delivers low dose of thrombin and systemic tranexamic acid and achieves high survival in swine with junctional hemorrhage10.1093/milmed/usad110 ↗
22. Control of junctional hemorrhage in a consensus swine model with hemostatic gauze products following minimal training10.7205/MILMED-D-14-00541 ↗
23. Ren, Z., Wang, Y., Wu, H., Cong, H., Yu, B., and Shen, Y. (2023). Preparation and application of hemostatic microspheres containing biological macromolecules and others. Int. J. Biol. Macromol., 257.10.1016/j.ijbiomac.2023.128299 ↗
24. Green preparation of hierarchically structured hemostatic epoxy -amine sponge10.1016/j.cej.2020.125445 ↗
25. Li, N., Yang, X., Liu, W., Xi, G., Wang, M., Liang, B., Ma, Z., Feng, Y., Chen, H., and Shi, C. (2018). Tannic acid cross-linked polysaccharide-based multifunctional hemostatic microparticles for the regulation of rapid wound healing. Macromol. Biosci., 18.10.1002/mabi.201800209 ↗
26. Li, L., Du, Y., Yin, Z., Li, L., Peng, H., Zheng, H., Yang, A., Li, H., and Lv, G. (2020). Preparation and the hemostatic property study of porous gelatin microspheres both in vitro and in vivo. Colloids Surf. B Biointerfaces, 187.10.1016/j.colsurfb.2019.110641 ↗
27. Hemostatic powders for gastrointestinal bleeding: A review of old, new, and emerging agents in a rapidly advancing field10.1055/a-1836-8962 ↗
28. Halting hemorrhage with self-propelling particles and local drug delivery10.1016/S0049-3848(16)30362-0 ↗
29. Targeted delivery of hemostats to complex bleeding wounds with magnetic guidance for instant hemostasis10.1016/j.cej.2021.130916 ↗
30. The efficacy and safety of topical tranexamic acid: A systematic review and meta-analysis10.1016/j.tmrv.2018.02.003 ↗
31. Hypocalcemia in trauma patients: A systematic review10.1097/TA.0000000000003027 ↗
32. Efficacy and safety of fibrinogen concentrate in trauma patients--a systematic review10.1016/j.jcrc.2013.12.011 ↗
33. Peng, H.T., and Siddiqui, M. (2023). Encapsulation of fibrinogen and thrombin with calcium carbonate for hemorrhage control. Biofunct. Mater., 1.10.55092/bm20230004 ↗
34. Morphology modification in freshly precipitated calcium carbonate particles using surfactant-polymer template10.1016/j.matlet.2016.10.043 ↗
35. Self-propelled particles that transport cargo through flowing blood and halt hemorrhage10.1126/sciadv.1500379 ↗
36. Stability of reconstituted fibrinogen concentrate in hemostatic function and concentration10.1093/milmed/usaa409 ↗
37. Peng, H., and Walford, D. (2020). Development of Biomaterials for Treating Battlefield Hemorrhage Part 1: Self-Propelling Particles, Defence Research and Development Canada, Toronto Research Centre. Report No. DRDC-RDDC-2020-R135.
38. A protocol for recombinant protein quantification by densitometry10.1002/mbo3.1027 ↗
39. Efficacy of hemostatic agents in humans with rotational thromboelastometry: An in-vitro study10.7205/MILMED-D-15-00417 ↗
40. Measuring short-term and long-term physiological stress effects by cortisol reactivity in saliva and hair10.1007/s00420-011-0727-3 ↗
41. Synthesis of calcium carbonate capsules in water-in-oil-in-water double emulsions10.1557/JMR.2008.0017 ↗
42. Tumor microenvironment modulating CaCO(3)-based colloidosomal microreactors can generally reinforce cancer immunotherapy10.1002/adma.202308254 ↗
43. Biochemical characterization, stability, and pathogen safety of a new fibrinogen concentrate (fibryga®)10.1016/j.biologicals.2017.12.003 ↗
44. Song, B., Yang, L., Han, L., and Jia, L. (2019). Metal ion-chelated tannic acid coating for hemostatic dressing. Materials, 12.10.3390/ma12111803 ↗
45. Peptide-immobilized starch/peg sponge with rapid shape recovery and dual-function for both uncontrolled and noncompressible hemorrhage10.1016/j.actbio.2019.08.039 ↗
46. Study on the hemolysis rate and cytotoxicity test of porous ultramicron ha containing mg10.4028/www.scientific.net/MSF.610-613.1215 ↗
47. Zhao, P., Tian, Y., You, J., Hu, X., and Liu, Y. (2022). Recent advances of calcium carbonate nanoparticles for biomedical applications. Bioengineering, 9.10.3390/bioengineering9110691 ↗
48. Advanced CaCO(3)-derived delivery systems for bioactive compounds10.1016/j.cis.2022.102791 ↗
49. Li, S.Y., and Lian, B. (2023). Application of calcium carbonate as a controlled release carrier for therapeutic drugs. Minerals, 13.10.3390/min13091136 ↗
50. Biny, L., Gerasimovich, E., Karaulov, A., Sukhanova, A., and Nabiev, I. (2024). Functionalized calcium carbonate-based microparticles as a versatile tool for targeted drug delivery and cancer treatment. Pharmaceutics, 16.10.20944/preprints202404.0315.v1 ↗
51. Recent advances in CO(2) bubble-generating carrier systems for localized controlled release10.1016/j.biomaterials.2017.04.018 ↗
52. Calcium carbonate: Controlled synthesis, surface functionalization, and nanostructured materials10.1039/D1CS00519G ↗
53. Fadia, P., Tyagi, S., Bhagat, S., Nair, A., Panchal, P., Dave, H., Dang, S., and Singh, S. (2021). Calcium carbonate nano- and microparticles: Synthesis methods and biological applications. 3 Biotech., 11.10.1007/s13205-021-02995-2 ↗
54. Calcium carbonate microcapsules encapsulating biomacromolecules10.1016/j.cej.2007.09.010 ↗
55. Immobilization of lipase from into calcium carbonate microcapsule and its use for enzymatic reactions in organic and aqueous media10.1016/j.molcatb.2014.08.009 ↗
56. Platelet-inspired intravenous nanomedicine for injury-targeted direct delivery of thrombin to augment hemostasis in coagulopathies10.1021/acsnano.2c05306 ↗
57. Biomimetic synthesis of calcium carbonate particles in a pseudovesicular double emulsion10.1021/la9705266 ↗
58. High loading efficiency and controlled release of bioactive immunotherapeutic proteins using vaterite nanoparticles10.1002/ppsc.202100012 ↗
59. The role of ph and ionic strength in the attraction–repulsion balance of fibrinogen interactions10.1021/acs.langmuir.1c01803 ↗
60. The effects of ph on the generation of turbidity and elasticity associated with fibrinogen-fibrin conversion by thrombin are remarkably influenced by sialic acid in fibrinogen10.1248/bpb.18.203 ↗
61. Encapsulation of proteins into CaCO3 by phase transition from vaterite to calcite10.1021/cg100631v ↗
62. Hierarchical porous calcium carbonate microspheres as drug delivery vector10.1016/j.pnsc.2017.11.005 ↗
63. Cooperativity between pepsin and crystallization of calcium carbonate in distilled water10.1016/S0162-0134(02)00573-1 ↗
64. A performance evaluation of commercial fibrinogen reference preparations and assays for clauss and pt-derived fibrinogen10.1055/s-0037-1613124 ↗
65. Solution stability of bovine fibrinogen10.1016/0049-3848(77)90006-8 ↗
66. Viscoelastic point-of-care tests for diagnosis of fibrinogen deficiency and guidance of fibrinogen administration in bleeding patients
67. Bioactive natural and synthetic polymers for wound repair10.1007/s13233-022-0062-4 ↗
68. Polyethylene glycol 6,000 enhancement of the clotting of fibrinogen solutions in visual and mechanical assays10.1016/0049-3848(74)90024-3 ↗
69. Modulating nanoparticle size to understand factors affecting hemostatic efficacy and maximize survival in a lethal inferior vena cava injury model10.1021/acsnano.1c09108 ↗
70. Guidelines on fibrinogen assays10.1046/j.1365-2141.2003.04256.x ↗
71. Rapid hemostasis in a sheep model using particles that propel thrombin and tranexamic acid10.1002/lary.26408 ↗
72. Self-propelling thrombin powder enables hemostasis with no observable recurrent bleeding or thrombosis over 3 days in a porcine model of upper gi bleeding10.1016/j.gie.2023.04.007 ↗
73. Preparation and characterization of phosphate-stabilized amorphous calcium carbonate nanoparticles and their application in curcumin delivery10.1016/j.matchemphys.2020.123552 ↗
74. CaCO(3) nanoparticles ph-sensitively induce blood coagulation as a potential strategy for starving tumor therapy10.1039/C9TB02684C ↗
75. Trauma-induced coagulopathy: Impact of the early coagulation support protocol on blood product consumption, mortality and costs10.1186/s13054-015-0817-9 ↗